N

Neumora Therapeutics Inc
NASDAQ:NMRA

Watchlist Manager
Neumora Therapeutics Inc
NASDAQ:NMRA
Watchlist
Price: 1.78 USD Market Closed
Market Cap: 293.3m USD

Relative Value

There is not enough data to reliably calculate the relative value of NMRA.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NMRA Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.7
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-5.7
Industry
21.5
Forward
-1.2
vs History
vs Industry
Median 3Y
-8.4
Median 5Y
-8.4
Industry
16.7
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-8.1
Industry
23
vs History
62
vs Industry
69
Median 3Y
3.7
Median 5Y
3.7
Industry
2.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.6
vs History
vs Industry
55
Median 3Y
-4
Median 5Y
-4
Industry
13.2
Forward
-0.6
vs History
vs Industry
52
Median 3Y
-4
Median 5Y
-4
Industry
16.6
Forward
-0.6
vs History
vs Industry
55
Median 3Y
-6.1
Median 5Y
-6.1
Industry
15.8
vs History
vs Industry
41
Median 3Y
-6
Median 5Y
-6
Industry
19
vs History
62
vs Industry
2
Median 3Y
41.7
Median 5Y
41.7
Industry
2

Multiples Across Competitors

NMRA Competitors Multiples
Neumora Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Neumora Therapeutics Inc
NASDAQ:NMRA
288.3m USD 0 -1.2 -0.6 -0.6
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.3 37.1 39.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.4B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
261.1B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
213.6B GBP 5 30.7 108.8 159.2
CH
Novartis AG
SIX:NOVN
210.5B CHF 4.8 18.5 11.7 15.2
US
Merck & Co Inc
NYSE:MRK
263.7B USD 4.1 13.9 9.8 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.6 14.1 9.8 11.4
IE
Endo International PLC
LSE:0Y5F
212.8B USD 91.8 -72.8 337 845
US
Pfizer Inc
NYSE:PFE
142B USD 2.3 14.4 7.4 10.1
P/E Multiple
Earnings Growth PEG
US
N
Neumora Therapeutics Inc
NASDAQ:NMRA
Average P/E: 24.3
Negative Multiple: -1.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.3
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.7
37%
0.8
CH
Novartis AG
SIX:NOVN
18.5
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -72.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.4
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
N
Neumora Therapeutics Inc
NASDAQ:NMRA
Average EV/EBITDA: 439.6
Negative Multiple: -0.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.1
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
11.7
6%
2
US
Merck & Co Inc
NYSE:MRK
9.8
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
1%
9.8
IE
E
Endo International PLC
LSE:0Y5F
337
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
N
Neumora Therapeutics Inc
NASDAQ:NMRA
Average EV/EBIT: 1 882.9
Negative Multiple: -0.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
CH
Novartis AG
SIX:NOVN
15.2
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
845
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4